FDA Approves Atezolizumab and Hyaluronidase-tqjs for Subcutaneous Injection
Evidence is based on the results from the IMscin001 study
Oncology News
ESMO oncology news aims to keep you up to date with the developments that affect you and your daily practice.
Make sure you check these pages frequently, or sign up to our newsletter! To sign up for ESMO newsletters, create a myESMO account here and select the newsletters you’d like to receive.
1548 results
Adjuvant Pembrolizumab Plus Chemotherapy Improves DFS in Patients with Newly-Diagnosed, High-Risk dMMR Endometrial Cancer, but Not in All-Comer Population
Findings from the ENGOT-en11/GOG-3053/KEYNOTE-B21 study
EMA Recommends Granting a Marketing Authorisation for Mirvetuximab Soravtansine
It is intended for the treatment of adult patients with FRα-positive, platinum-resistant high grade serous epithelial ovarian, Fallopian tube, or primary peritoneal cancer
Substantial and Durable Overall and Intracranial Activity of Trastuzumab Deruxtecan in Previously Treated HER2-positive mBC Including a Large Cohort of Patients with Brain Metastases
Primary results from the DESTINY-Breast12 study
No Survival Benefit from Adding Preoperative Chemoradiotherapy to Perioperative Chemotherapy in Patients with Resectable Gastric/GEJ Adenocarcinoma
Findings from the TOPGEAR study
Adjuvant Pembrolizumab Prolongs DFS Among Patients with High-Risk Muscle Invasive Urothelial Carcinoma
Findings from the AMBASSADOR study
FDA Approves Amivantamab-vmjw with Carboplatin and Pemetrexed for NSCLC with EGFR Exon 19 Deletions or L858R Mutations
Evidence for efficacy is based on the results from the MARIPOSA-2 study
177Lu-PSMA-617 Prolongs rPFS Relative to Androgen Receptor Pathway Inhibitor Change, with a Favourable Safety Profile in Patients with PSMA-positive mCRPC
Findings from the PSMAfore study
Inhibition of GDF-15 with Ponsegromab Results in Increased Weight Gain and Overall Activity Level and Reduced Cancer Cachexia Symptoms
Findings from a randomised phase II study
FDA Approves Pembrolizumab with Chemotherapy for Unresectable Advanced or Metastatic Malignant Pleural Mesothelioma
Evidence for efficacy is based on the results from the KEYNOTE-483 study
FDA Approves Neoadjuvant/Adjuvant Durvalumab for Patients with Resectable NSCLC
Evidence for efficacy is based on the results from the AEGEAN study
Sacituzumab Govitecan Demonstrates a Relatively High ORR with Rapid Responses in Cisplatin-Ineligible Patients with mUC Progressing to Previous Treatment with ICI
Findings from the TROPHY-U-01 Cohort 2 study